By John Revill and Byron Kaye ZURICH/SYDNEY (Reuters) -Vifor Pharma’s shares surged more than 15% in early trading on Monday after the Swiss drugmaker and Australia’s CSL both confirmed they ...

Vifor Pharma has forged a strategic partnership with Fresenius Kabi, focusing on marketing a portfolio of iron deficiency drugs.

CSL Vifor offers a communication campaign to answer EU allegations it disparaged a rival iron deficiency treatment from Pharmacosmos.

Here's why these Australian stocks could be among the best to buy and hold forever right now. Let's dig deeper into ...

The developer funds will be used to build "hundreds" of new affordable houses across England, Scotland, Wales and Northern ...

ASX health stocks fall o.92% over past five days as US President Donald Trump renews threat to impose tariffs on pharmaceutical imports.

The government will allocate the payment to affordable homes programmes across all four nations, including giving funding ...

Here's one S&P/ASX 300 Index (ASX: XKO) share that Stuart Bromley of Medallion Financial Group rates a buy and one that's a ...

CSL will consolidate its R&D teams around six sites located in biotech hubs as the company looks to boost external ...

More states, territories and Washington, D.C., have signed on to a settlement with drugmaker Purdue Pharma and the Sackler family over the opioid crisis, officials said.

MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival.

Verona Pharma plc (NASDAQ:VRNA) is among the 10 Best Growth Stocks Under $100 to Buy Now. Analysts at Jefferies have raised the price target for Verona Pharma plc (NASDAQ:VRNA) to $110, up from ...